FOLH1 and prostate cancer: Another compound, NODAGA-Zoledronate, also achieved quantitative yields when radiolabeled with 68Ga [142] and demonstrated its clinical value in the detection of bone metastases in prostate cancer patients who experienced PSA progression on PSMA-based radioligand therapy or in the setting of restaging [143,144].